Researchers launched a unique collaboration on Wednesday aimed at getting cancer drugs to the market more quickly in which three companies will cooperate with the U.S. government and non-profit groups to test five experimental breast cancer drugs.
The five-year, $26 million study called Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis, or I-SPY2, will aim to use DNA to match the best drug to each patient and to more quickly toss out approaches that do not work or are too toxic.
"They'll get the latest and greatest in terms of targeted drugs," Dr. Anna Barker, deputy director of the National Cancer Institute, said in an interview.
"I think it's the future. Government couldn't have done it on their own and these companies couldn't have done it on their own."
Unusually, the companies agreed to share information on using genes to predict how well a patient will respond as part of the Biomarkers Consortium, which includes the U.S. Food and Drug Administration and the National Institutes of Health.
"I-SPY 2 will provide a path to personalized medicine," said Dr. Laura Esserman, a breast cancer surgeon at the University of California San Francisco who will help lead the clinical trials. "We intend that every drug will graduate with a companion marker."
The trial will match patients to one of five experimental drugs:
-- ABT-888 or veliparib, being developed by Abbott Laboratories. The pill is a PARP inhibitor, which blocks a cell repair enzyme used by cancer cells.
-- AMG 655 or conatumumab, a targeted drug being developed by Amgen. It boosts a protein called APO/TRAIL that causes cancer cells to self-destruct.
-- Amgen's AMG 386, an angiogenesis inhibitor that stops tumors from growing blood vessels to nourish themselves.
-- CP-751,871 or figitumumab, being developed by Pfizer Inc to target the insulin growth factor receptor or IGFR.
-- Pfizer's HKI-272 or neratinib, another targeted therapy called a Pan ErbB inhibitor that targets several related receptors used by cancer cells.
The group is negotiating with other companies to add their experimental drugs to the mix.
"It'll speed up the whole process," Barker said.
The drug company lobby group PhRMA estimates it can take as long as 15 years and cost more than $1.3 billion dollars to take a new drug from laboratory to pharmacy.
Patients at 20 cancer centers will be tested right after they get tiny samples of tissue taken in biopsies. Before they ever get surgery, they will be treated with one of the drugs to see if this helps prevent tumor spread.
Up to 12 different cancer drugs will be tested. Unusually, the group has FDA approval to drop and add drugs throughout the course of the trial without having to stop it to write a whole new protocol.
Beef and wine producer Uruguay is branching out into caviar
The Arabic word Shifa means healing and the Al-Shifa clinic is a place compassion for the sick and service to the needy, one of the most important teachings of Islam.
Worst water shortage in 50 years sees residents of Harare turning to unhygienic supplies
In the face of prejudice, Noelia Garcia is the first person with Down syndrome to work as a preschool teacher in Argentina — and one of the few in the world.
Outbreak linked to heavy rains which encourage mosquito breeding
UN report warns that without measures to halt and reverse climate change, food production could become impossible in large areas of the world
It called for a "broad-based transformation of food and agricultural systems" to adapt to a warmer world, with an emphasis on supporting small shareholders.
A pre-COP22 ministerial meeting will be held in Morocco ahead of the conference to be held in Marrakech in November
Nearly 30-hour operation performed on 13-month-old boys
Among the world's wealthier regions, North America had the worst healthy life expectancy at birth for both men and women.
Diminishing coal in the energy mix must become a government policy in EU towards a low carbon economy: European think-tank
'Developing countries should be given access to nuclear power,' says International Atomic Energy Agency director
More people in the world are obese than underweight
Epipen maker Mylan has agreed to pay $465 million to the US government
3 of 4 transplants from living donors removed; scientists hope remaining transplant successful
Air monitoring station clocks dangerously high levels of smog